Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Advanced Tech.
8 min read
Inventory of GPCR Targeted Drugs Applying for Listing (I)
10 October 2023
This article will review currently applied listed GPCR-targeting drugs, and the associated popular GPCR class targets and drug development opportunities worth paying attention to.
Drug Insights
4 min read
Deep Scientific Insights on Panitumumab's R&D Progress, Mechanism of Action, and Drug Target
9 October 2023
This article summarized the latest R&D progress of Panitumumab, the Mechanism of Action for Panitumumab, and the drug target R&D trends for Panitumumab.
Latest Hotspot
3 min read
First Participant Administered in Stage 1b Clinical Evaluation of STK-012, Intended for Therapy of Solid Tumors
9 October 2023
STK-012 is designed specifically to activate antigen-triggered T cells, crucial for powerful anti-cancer effects, while avoiding broader activation of other lymphocytes, such as NK cells related to IL-2 toxicity.
Drug Insights
4 min read
An In-depth Analysis of Olopatadine hydrochloride's R&D Progress
9 October 2023
This article summarized the latest R&D progress of Olopatadine hydrochloride, the Mechanism of Action for Olopatadine hydrochloride, and the drug target R&D trends for Olopatadine hydrochloride.
R&D Pipeline
8 min read
Discussing the invalidation of parts of Upadacitinib patents and the dissolution of Reistone Biopharma, a subsidiary of Jiangsu Hengrui Pharmaceutical
9 October 2023
On the night of September 14, market rumors indicated that Jiangsu Hengrui Pharmaceutical was about to dissolve its subsidiary, Reistone Biopharma.
Drug Insights
4 min read
Norfloxacin: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
9 October 2023
This article summarized the latest R&D progress of Norfloxacin, the Mechanism of Action for Norfloxacin, and the drug target R&D trends for Norfloxacin.
Latest Hotspot
4 min read
ELAHERE® Demonstrates Advantage in Overall and Progression-Free Survival in Ovarian Cancer
9 October 2023
ImmunoGen Inc. shared outcomes from two assessments of the MIRASOL Phase 3 trial. The trial evaluated safety and effectiveness of ELAHERE® in platinum-resistant ovarian cancer patients positive for the folate receptor alpha, versus chemotherapy.
Drug Insights
4 min read
Nizatidine Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
9 October 2023
This article summarized the latest R&D progress of Nizatidine, the Mechanism of Action for Nizatidine, and the drug target R&D trends for Nizatidine.
Advanced Tech.
8 min read
Interpretation of Gene Therapy Company
9 October 2023
Gene Therapy Company focuses on correcting or compensating for diseases caused by abnormal genes by introducing foreign normal genes into target cells.
Drug Insights
4 min read
Unleashing the Power of Nitrazepam: A Comprehensive Review on R&D Breakthroughs, Action Mechanisms, and Drug Target
9 October 2023
This article summarized the latest R&D progress of Nitrazepam, the Mechanism of Action for Nitrazepam, and the drug target R&D trends for Nitrazepam.
Latest Hotspot
3 min read
MARIPOSA Phase 3 study hits key target, showing improved effectiveness of RYBREVANT® and Lazertinib versus Osimertinib for EGFR-Mut patients
9 October 2023
Landmark Phase 3 MARIPOSA Study achieves its main goal, demonstrating clinically relevant enhancement for RYBREVANT® and Lazertinib when compared to Osimertinib in EGFR-Mut patients.
Drug Insights
4 min read
A Comprehensive Review of Nimesulide's R&D Innovations and Drug Target Mechanism
9 October 2023
This article summarized the latest R&D progress of Nimesulide, the Mechanism of Action for Nimesulide, and the drug target R&D trends for Nimesulide.